Evidence map›Paper›PMID 26493689›Full record

ArticleScientific reports2015

Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer.

Chiao-Wen Kang, Avijit Dutta, Li-Yuan Chang, Jayashri Mahalingam, Yung-Chang Lin, Jy-Ming Chiang, Chen-Yu Hsu, Ching-Tai Huang, Wan-Ting Su, Yu-Yi Chu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 153 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chiao-Wen KangGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Avijit DuttaDivision of Infectious Diseases, Department of Medicine, Chang Gung Memorial Hospital and Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Li-Yuan ChangGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Jayashri MahalingamDivision of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Yung-Chang LinDivision of Hematooncology, Department of Medicine, Chang Gung Memorial Hospital and Chang Gung University, Kweishan, 333, Taoyuan, Taiwan.
Jy-Ming ChiangColorectal Surgery Section, Department of Surgery, Chang Gung Memorial Hospital and Chang Gung University, Kweishan- 333, Tayouan, Taiwan.
Chen-Yu HsuDivision of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Ching-Tai HuangDivision of Infectious Diseases, Department of Medicine, Chang Gung Memorial Hospital and Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Wan-Ting SuDivision of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Yu-Yi ChuDivision of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Chun-Yen LinGraduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Kweishan- 333, Taoyuan, Taiwan.
Chang Gung Memorial Hospital · TWChang Gung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TIM-3 functions to enforce CD8+ T cell exhaustion, a dysfunctional state associated with the tolerization of tumor microenvironment. Here we report apoptosis of IFN-γ competent TIM-3+ population of tumor-infiltrating CD8+ T cells in colon cancer. In humans suffering from colorectal cancer, TIM-3+ population is higher in cancer tissue-resident relative to peripheral blood CD8+ T cells. Both the TIM-3+ and TIM-3- cancer tissue-resident CD8+ T cells secrete IFN-γ of comparable levels, although apoptotic cells are more in TIM-3+ compared to TIM-3- population. In mouse CT26 colon tumor model, majority of tumor-infiltrating CD8+ T cells express TIM-3 and execute cytolysis function with higher effector cytokine secretion and apoptosis in TIM-3+ compared to TIM-3- population. The tumor cells secrete galectin-9, which increases apoptosis of tumor-infiltrating CD8+ T cells. Galectin-9/TIM-3 signaling blockade with anti-TIM-3 antibody reduces the apoptosis and in addition, inhibits tumor growth in mice. The blockade increases therapeutic efficacy of cyclophosphamide to treat tumor in mice as well. These results reveal a previously unexplored role of TIM-3 on tumor-infiltrating CD8+ T cells in vivo.

Indexed as

ApoptosisCD8-Positive T-LymphocytesColonic NeoplasmsGalectinsHepatitis A Virus Cellular Receptor 2HumansMembrane ProteinsGalectinsHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2LGALS9 protein, humanMembrane Proteins

Identifiers

PMID26493689
PMCPMC4616166
OpenAlexW2413897266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.